MINNEAPOLIS, MN / ACCESS Newswire / December 23, 2025 / PetVivo Holdings, Inc. (OTCQX:PETV)(OTCID:PETVW), in cooperation with its wholly-owned subsidiaries PetVivo Animal Health, Inc. and PetVivo AI, Inc., a leading provider of medical devices and biomedical therapeutics for equines and companion animals, today announced that it will participate in the DealFlow Discovery Conference, taking place January 28-29, 2026. John Lai, Chief Executive Officer of PetVivo Holdings, Inc., will deliver a company presenta ...

Revolutionary Veterinary AI Platform Ditches Dense Documentation in Favor of Clear, Engaging Video Walkthrough MINNEAPOLIS, MN, Dec. 16, 2025 (GLOBE NEWSWIRE) -- PetVivo.ai, the AI powered platform transforming how veterinary practices connect with pet parents, today announced something different: instead of another lengthy press release filled with jargon, they made a video. "Let's be honest," said John Lai, CEO at PetVivo Holdings (OTCQX: PETV; OTCID: PETVW). "Most tech launches are too complicated and to ...

Core Insights - PetVivo.ai has launched an AI platform aimed at transforming the $150 billion pet care market by significantly reducing customer acquisition costs for veterinary practices [2][4][9] Group 1: Company Overview - PetVivo Holdings, Inc. is focused on commercializing innovative medical products and therapeutics for companion animals and horses [2][12] - The company has introduced PetVivo.ai, an AI-driven Software-as-a-Service (SaaS) platform that enhances its existing product portfolio [3][10] Group 2: Market Opportunity - The pet care industry exceeds $150 billion annually, with Gen Z and Millennial pet parents making up 57% of pet owners, who expect modern digital experiences [4][8] - There are approximately 30,000 veterinary practices in the U.S. and over 100,000 worldwide, indicating a large and under-digitized market for PetVivo.ai [8] Group 3: Product and Technology - PetVivo.ai utilizes nine specialized AI agents to connect veterinary practices with pet owners, improving lead generation and customer engagement [5][10] - The platform has demonstrated a customer acquisition cost of $42.53, significantly lower than the typical $80–$400 spent by veterinary practices [2][7] Group 4: Financial Metrics - In a beta program, the median practice acquired 47 new clients over six months, achieving a blended customer acquisition cost of $42.53 [5][7] - The platform offers a pricing model starting at $1,999 per month, with gross margins between 80% and 90% [7] Group 5: Competitive Advantages - PetVivo.ai holds a first-mover advantage in the AI-driven veterinary market, with no direct competitors and strong network effects [10] - The company has established relationships with 1,200 veterinary clinic distributors and plans to expand to over 7,000 [10] Group 6: Valuation Potential - The launch of PetVivo.ai is expected to transition the company from traditional medical device revenue multiples (1–2x) to AI SaaS multiples (15–30x), indicating potential valuation upside [9]

Core Insights - PetVivo Holdings, Inc. has launched PetVivo.ai, an AI platform aimed at transforming the $150 billion pet care market by significantly reducing customer acquisition costs for veterinary practices [1][3][4] - The company is shifting from traditional medical device sales to a high-margin AI Software-as-a-Service (SaaS) model, which offers recurring revenue and scalability [2][5] Industry Context - The pet care industry exceeds $150 billion annually, with Gen Z and Millennial pet owners making up 57% of all pet owners, who expect modern digital experiences [3] - Veterinary practices currently rely on outdated marketing methods, leading to high customer acquisition costs ranging from $80 to $400 per new client [3][4] Company Strategy - PetVivo.ai utilizes nine specialized AI agents to connect veterinary practices with engaged pet parents, generating qualified leads at a cost of $3 per pet parent, compared to traditional methods costing $15 to $45 [4][6] - The platform's beta program showed that the median practice acquired 47 new clients over six months at a blended customer acquisition cost of $42.53, achieving significant savings [4][6] Financial Metrics - The platform is expected to achieve gross margins of 80-90% and a lifetime value to customer acquisition cost (LTV/CAC) ratio of 25:1 [6] - Projections indicate that by Year 1, the company could reach $12 million in annual recurring revenue (ARR) with 500 practices, scaling to $360 million ARR with 10,000 practices by Year 5 [6] Market Opportunity - PetVivo.ai targets approximately 30,000 U.S. veterinary practices and over 100,000 globally, with strong scaling potential even under conservative adoption forecasts [5][6] - The launch is seen as a catalyst for re-evaluating the company's valuation, transitioning from traditional medical device revenue multiples of 1-2x to AI SaaS multiples of 15-30x [5][7] Competitive Advantages - PetVivo.ai holds a first-mover advantage with no direct AI competitors and strong two-sided network effects, supported by existing relationships with 1,200 veterinary clinic distributors [7] - Deep integrations with practice management systems are expected to facilitate adoption and reduce onboarding friction [7] Commercial Launch - Following successful beta testing, PetVivo.ai is now fully commercial with open sign-ups, offering a 14-day free trial and three pricing tiers [8]

Core Insights - PetVivo Holdings, Inc. is set to launch its veterinary platform in Q1 2026, supported by a comprehensive technical whitepaper from its AI technology partner, Digital Landia Holding Corp. [1][11] Technical Validation - The whitepaper confirms the technical foundation of PetVivo's exclusive 10-year licensing agreement, showcasing a multi-agent AI architecture that offers significant clinical and economic benefits for veterinary practices [2][9]. - The CEO of PetVivo emphasized that the whitepaper validates a production-ready AI framework with clinical utility and enterprise-grade architecture [3]. Framework Capabilities - The AI framework addresses key challenges in veterinary practices, including a 90% to 98% reduction in client acquisition costs and universal diagnostic assistance through nine specialized AI agents [4]. - The platform is designed to enhance access to the Gen Z market with a mobile-first consumer experience [4]. Intellectual Property - The whitepaper outlines five patent-pending innovations that protect the core functionality of the AgenticPet framework, providing competitive advantages under the licensing agreement [5]. Enterprise Architecture - The architecture is tailored for veterinary practices, featuring end-to-end encryption, blockchain audit trails, and HIPAA-aligned privacy frameworks, ensuring over 99.9% uptime reliability [6][7]. Distribution Network - PetVivo has an established distribution network, including a partnership with Veterinary Growth Partners, which has over 7,300 veterinary professional members, positioning the company for rapid deployment of the AgenticPet platform [7]. Strategic Rationale - The exclusive 10-year licensing agreement reflects PetVivo's confidence in the framework's competitive positioning and potential revenue streams, including B2B subscriptions and lead-generation fees [9]. Partnership Milestones - The publication of the whitepaper marks the third major milestone in the PetVivo–Digital Landia partnership, following the strategic alliance announcement and the exclusive licensing agreement [10]. Upcoming Launch - The technical foundation supports a dual-platform launch in Q1 2026, featuring both a B2C app and a B2B veterinary platform with AI diagnostic assistance [11].

Financial Data and Key Metrics Changes - The company reported revenues of $303,000 for the quarter, representing a 51% increase compared to the same quarter last year [8] - For the first half of the fiscal year, revenues increased by 85% to over $600,000, marking the best first half ever for the company [5][8] - Gross profit totaled $220,000, or 72.6% of revenues, which was a 23% increase from $180,000, or 89.5% of revenues in the same quarter a year ago [9] - Net loss totaled $3 million, or $0.11 per share, compared to a net loss of $2.2 million in the same quarter last year [10] - Available cash increased to $768,000 from $220,000 at the end of the previous fiscal year [11] Business Line Data and Key Metrics Changes - The U.S. distributor network increased sales by 35% year-over-year, contributing $237,000, or 75% of total revenues for the quarter [4][8] - The new product, Precise PRP, generated increased revenue during the quarter, with 42% of revenue attributed to PRP and 58% to Spring [34] Market Data and Key Metrics Changes - The veterinary healthcare market in Mexico is projected to grow at a CAGR of 11%, reaching approximately $2.4 billion in six years [3] - The European animal market is estimated at over $16.56 billion and is projected to grow at a CAGR of 8.6% [3] - The U.K. market exceeds $2.6 billion and is growing at a 7.8% CAGR [4] Company Strategy and Development Direction - The company aims to expand the use of its flagship product, Spring, and increase awareness of Precise PRP for treating osteoarthritis in animals [13] - The company is exploring the introduction of products to human markets and has formed partnerships to enhance its market presence [7][18] - A strategic collaboration with Digital Landia aims to integrate AI technology into the company's platform, enhancing diagnostic capabilities [21][22] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in continued strong sales momentum and market penetration for the remainder of fiscal 2026 [27] - The company anticipates another year of record growth and improving bottom line as it expands the use of Spring and Precise PRP [27] - The third and fourth quarters are expected to be particularly strong due to increased industry events driving product awareness [28] Other Important Information - The company qualified to begin trading on the OTCQX best market, enhancing visibility and liquidity for investors [12] - The appointment of Josh Rubin to the board of directors is expected to provide valuable insights into growth-stage companies [6] Q&A Session Summary Question: How many clinics are heavy users of the product? - The learning curve for veterinarians to adopt the product ranges from six months to a year, with anecdotal evidence showing continued growth in adoption [32] Question: Can you break down the revenue between Spring and PRP? - Approximately 42% of revenue was from PRP and 58% from Spring, with the PRP revenue only reflecting the canine version as equine shipments just began [34][35] Question: Do you have any corporate clinics that have adopted your product corporate-wide? - No corporate-wide adoption has occurred yet, as each corporate clinic allows veterinarians to make their own decisions [37] Question: Can you provide a breakdown between companion versus equine revenue? - The company tracks these markets separately and plans to provide more detailed segment reporting in the future [39]

Core Insights - PetVivo Holdings, Inc. reported a 51% increase in revenues for the second quarter of fiscal year 2026, totaling $303,000, driven by the introduction of the new product line PrecisePRP and expansion into the companion animal market [7][19][21] - The company has successfully entered the European market through a partnership with Nupsala Group, enhancing its distribution capabilities [6][16] - PetVivo's strategic collaborations, including with Digital Landia and Commonwealth Markets, are expected to enhance product adoption and market presence [10][17][18] Fiscal Q2 Financial Highlights - Revenues increased to $303,000, up 51% from the same quarter last year, marking a record for the second fiscal quarter [7][19] - Gross profit rose to $220,000, with a gross margin of 72.6%, an improvement from 63.8% in the previous quarter [20] - Operating loss increased to $2.1 million, while net loss rose to $3.0 million, reflecting increased sales and marketing expenses [21][22] Fiscal Q2 Operational Highlights - The company engaged additional distributors to support domestic and international expansion, with national distributor network sales increasing by 35% [7][19] - PetVivo's flagship product, Spryng with OsteoCushion Technology, has been adopted by over 1,200 veterinary clinics across the U.S. [17] - The company launched three new continuing education courses for veterinary professionals to enhance expertise in osteoarthritis and regenerative modalities [13] Strategic Partnerships and Innovations - A strategic partnership with Digital Landia aims to integrate AI technology into PetVivo's veterinary products, potentially reducing client acquisition costs significantly [10][18] - The collaboration with Commonwealth Markets has led to the integration of Spryng and PrecisePRP into care protocols for thoroughbred horses [17] - Ongoing research with PiezoBioMembrane is focused on developing biodegradable piezoelectric materials for regenerative applications [12][15] Financial Outlook - Management anticipates continued record growth for the full fiscal year ending March 31, 2026, driven by the expansion of Spryng and PrecisePRP [24][25] - The U.S. animal health market is projected to double to $11.3 billion by 2030, providing significant growth opportunities for PetVivo [18]

Revenue Performance - Revenues for the three months ended September 30, 2025, were $303,284, an increase from $200,720 in the same period of 2024, driven by sales of PrecisePRP™ products[146] - Sales of Spryng® products accounted for $186,902, while PrecisePRP™ products contributed $116,382 to total revenues for the three months ended September 30, 2025[146] - Total revenues for the six months ended September 30, 2025, were $600,784, up from $324,470 in the same period of 2024, driven by sales of PrecisePRP™ products[155] Cost and Expenses - Cost of sales increased to $83,226 for the three months ended September 30, 2025, compared to $21,162 in the same period of 2024, primarily due to the introduction of PrecisePRP™ products[147] - Operating expenses decreased to $2,285,425 for the three months ended September 30, 2025, from $2,352,598 in the same period of 2024, attributed to lower general and administrative and research and development expenses[148] - General and administrative ("G&A") expenses decreased to $1,236,730 for Q3 2025 from $1,267,117 in Q3 2024, reflecting cost-cutting initiatives[149] - Sales and marketing expenses increased to $787,262 in Q3 2025 from $620,307 in Q3 2024, driven by support for the launch of Spryng® and PrecisePRP™ products[150] - Research and development ("R&D") expenses decreased to $261,433 in Q3 2025 from $465,174 in Q3 2024, primarily due to reduced clinical studies[151] - Operating expenses decreased to $4,316,468 for the six months ended September 30, 2025, from $4,507,787 in 2024, mainly due to lower G&A and sales and marketing expenses[157] Net Loss - The net loss for the three months ended September 30, 2025, was $3,007,809, compared to a net loss of $2,175,493 for the same period in 2024[145] - Net loss for Q3 2025 was $3,007,809 or ($0.11) per share, compared to a net loss of $2,175,493 or ($0.11) per share in Q3 2024[154] Cash Flow and Assets - The company reported a net cash used in operating activities of $3,828,209 for the six months ended September 30, 2025, primarily due to the net loss and a decrease in accounts payable[166] - As of September 30, 2025, current assets were $2,109,723, with cash and cash equivalents at $767,914, while current liabilities were $1,052,694[164] Product Development and Market Presence - The company has a pipeline of therapeutic devices for both veterinary and human clinical applications, with plans to expand through acquisitions or in-licensing of proprietary products[142] - The company has entered into an Exclusive License and Supply Agreement with VetStem, allowing it to sell PrecisePRP™ products, enhancing its product offerings in the veterinary market[133] - Spryng® has been administered to over 2,000 horses and dogs since its introduction, demonstrating its market acceptance and effectiveness[140] - The company operates from an ISO 7 certified clean room manufacturing facility and plans to open a second facility to minimize supply risks and expand production capacity[141]

Core Insights - PetVivo Holdings, Inc. will hold a conference call on November 14, 2025, to discuss its fiscal second quarter results for the period ending September 30, 2025 [1][2] - The company focuses on innovative medical devices and therapeutics for companion animals, leveraging human therapies for efficient treatment [4] - PetVivo has a strong product pipeline, including SPRYNG with OsteoCushion technology and PrecisePRP, both currently available for commercial sale [5] Company Overview - PetVivo Holdings, Inc. operates through its subsidiary PetVivo Animal Health, Inc., specializing in biomedical devices for companion animals [4] - The company aims to bring veterinary medical devices to market faster than more regulated pharmaceuticals, enhancing revenue timelines [4] - PetVivo holds a portfolio of twelve patents and six trade secrets protecting its biomaterials and products [5] Upcoming Events - The conference call will include a presentation by management followed by a Q&A session [2] - Dial-in information for the conference call includes a toll-free number and a specific conference ID and passcode [2] - A replay of the conference call will be available on the company's website [3]

Core Insights - PetVivo Holdings, Inc. has appointed Josh Ruben to its Board of Directors, enhancing its leadership team with expertise in healthcare finance and corporate strategy [1][2][4] - Ruben's background includes significant experience in executing multi-billion-dollar mergers and acquisitions, which will support PetVivo's growth and market expansion efforts [2][4] - The company focuses on innovative medical therapeutics for companion animals, particularly in treating osteoarthritis and joint conditions [2][6] Company Overview - PetVivo Holdings, Inc. operates in the biomedical device sector, specifically targeting the commercialization of medical devices and therapeutics for companion animals [6] - The company aims to leverage human therapies for animal treatment, allowing for a quicker market entry compared to traditional pharmaceuticals [6] - PetVivo has a diverse product pipeline, including its lead product SPRYNG, which utilizes OsteoCushion technology for joint-related afflictions in animals [7] Leadership and Strategy - Josh Ruben, as the Managing Director of Life Sciences at Trinity Capital, brings a wealth of experience in venture lending and investment banking, particularly in life sciences [4][5] - His expertise will be instrumental in guiding PetVivo's capital strategy and maximizing value creation across veterinary and emerging human applications [5] - The company holds a portfolio of twelve patents and six trade secrets, protecting its innovative biomaterials and production processes [7]